Insmed shares skyrocket 103% on positive late-stage results for rare lung disease therapy - MarketWatch

STAT

Insmed shares skyrocket 103% on positive late-stage results for rare lung disease therapy MarketWatch Insmed Inc. INSM, -1.05% shares skyrocketed 102.9% in premarket trade Tuesday after the company announced that a phase 3 trial for its rare lung disease therapy met its primary endpoint. The company said it plans to pursue accelerated approval for the ... Insmed inhaled antibiotic clears rare lung disease in pivotal studySTAT Insmed's lung drug meets main goal in late-stage studyReuters Insmed (INSM) Reports Positive Top-Line Results from Phase 3 CONVERT Study of ALISStreetInsider.com Endpoints News all 5 news articles »

from Health - Google News http://ift.tt/2w2Ol7x